Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in Patients with HIV and Hepatitis C Virus Coinfection
Open Access
- 1 January 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (1) , 137-143
- https://doi.org/10.1086/524080
Abstract
Background. We analyzed the effect of exposure to nonnucleoside reverse‐transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) on the progression of liver fibrosis in patients with human immunodeficiency virus (HIV) and hepatitis C virus coinfection. Methods. We analyzed data and liver biopsy findings for 201 coinfected patients. Fibrosis was scored following the French METAVIR Cooperative Study Group. We used multinomial logistic regression analysis and the fibrosis progression rate to assess the association between cumulative exposure to antiretroviral drugs and stage of fibrosis. Results. The adjusted odds ratio (AOR) and 95% confidence interval (CI) of having a fibrosis stage score of 0 or 1, compared with 3 or 4, increased with each additional year of exposure to HAART (AOR, 1.32; 95% CI, 1.04–1,67), to NNRTIs as a class (AOR, 1.64; 95% CI, 1.18–2.27), to efavirenz (AOR, 1.54; 95% CI, 1.03–2.30), and to nevirapine (AOR, 1.72; 95% CI, 1.15–2.78). This effect was not found with PIs as a class. The AOR (95% CI) of having a fibrosis stage score of 2 versus 3 or 4 increased with each additional year of exposure to NNRTIs (AOR, 1.51; 95% CI, 1.08–2.10) and nevirapine (AOR, 1.58; 95% CI, 1.06–2.37). This effect was not found with highly active antiretroviral therapy, PIs, or efavirenz. The AOR (95% CI) of having a fibrosis progression rate ⩽0.1 versus >0.1 increased with each additional year of exposure to highly active antiretroviral therapy (AOR, 1.31; 95% CI, 1.07–1.60), to NNRTIs (AOR, 1.33; 95% CI, 1.03–1.70), and to nevirapine (AOR, 1.44; 95% CI, 1.07–1.95). This effect was not found with PIs or with efavirenz. Conclusions. In contrast with previous studies, we found that exposure to NNRTIs was clearly associated with a reduction in fibrosis progression, whereas exposure to PIs was not. Of note, exposure to nevirapine was more consistently associated with a reduction in fibrosis progression than was exposure to efavirenz. Prospective work is needed in this area.Keywords
This publication has 32 references indexed in Scilit:
- Do Type and Duration of Antiretroviral Therapy Attenuate Liver Fibrosis in HIV--Hepatitis C Virus--Coinfected Patients?Clinical Infectious Diseases, 2006
- Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct–ligated rats†Hepatology, 2005
- The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfectionHepatology, 2004
- Survival in patients with HIV infection and viral hepatitis B or CAIDS, 2004
- Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis CAIDS, 2004
- Progression of Chronic Hepatitis C to Liver Fibrosis and Cirrhosis in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency VirusClinical Infectious Diseases, 2003
- Mortality among Human Immunodeficiency Virus-Infected Patients with Cirrhosis or Hepatocellular Carcinoma Due to Hepatitis C Virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997Clinical Infectious Diseases, 2001
- Impact of Human Immunodeficiency Virus Infection on Progression to End‐Stage Liver Disease in Individuals with Hemophilia and Hepatitis C Virus InfectionThe Journal of Infectious Diseases, 2001
- Liver Fibrosis Progression Is Related to CD4 Cell Depletion in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency VirusThe Journal of Infectious Diseases, 2001
- Human immunodeficiency virus infection modified the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosisJournal of Hepatology, 1997